Clinical trial
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With…
NCT00139698 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00139698 |
|---|---|
| Title | Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension |
| Official title | A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension |
| Acronym | OSCAR |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Essential Hypertension |
| Intervention type | Drug |
| Interventions | olmesartan alone or in combination with hydrochlorothiazide |
| Enrollment | 410 |
| Start date | Sep 1, 2005 |
| Completion | Jul 1, 2006 |
| First posted | Aug 31, 2005 |
| Last update posted | Dec 5, 2018 |
| Countries | Colombia, Ecuador, Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: